National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, 00161 Rome, Italy.
Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, 40127 Bologna, Italy.
Int J Mol Sci. 2022 Jul 4;23(13):7426. doi: 10.3390/ijms23137426.
Recently, several chemotherapeutic drugs have been repositioned in neurological diseases, based on common biological backgrounds and the inverse comorbidity between cancer and neurodegenerative diseases. Fenretinide (all-trans-N-(4-hydroxyphenyl) retinamide, 4-HPR) is a synthetic derivative of all-trans-retinoic acid initially proposed in anticancer therapy for its antitumor effects combined with limited toxicity. Subsequently, fenretinide has been proposed for other diseases, for which it was not intentionally designed for, due to its ability to influence different biological pathways, providing a broad spectrum of pharmacological effects. Here, we review the most relevant preclinical and clinical findings from fenretinide and discuss its therapeutic role towards cancer and neurological diseases, highlighting the hormetic behavior of this pleiotropic molecule.
最近，几种化疗药物在神经疾病中被重新定位，这是基于癌症和神经退行性疾病之间共同的生物学背景和反向共病性。芬维 A 胺（全反式-N-（4-羟基苯基）维 A 酰胺，4-HPR）是全反式维 A 酸的合成衍生物，最初在抗癌治疗中因其抗肿瘤作用和有限的毒性而被提出。随后，由于其能够影响不同的生物途径，提供广泛的药理作用，芬维 A 胺已被提议用于其他疾病，尽管这些疾病并非其最初设计的适应症。在这里，我们综述了芬维 A 胺的最相关的临床前和临床研究结果，并讨论了其在癌症和神经疾病方面的治疗作用，突出了这种多效分子的类药性行为。
